Werewolf Therapeutics Management
Management criteria checks 3/4
Werewolf Therapeutics' CEO is Dan Hicklin, appointed in Oct 2017, has a tenure of 7.33 years. total yearly compensation is $1.37M, comprised of 42.7% salary and 57.3% bonuses, including company stock and options. directly owns 1.45% of the company’s shares, worth $912.34K. The average tenure of the management team and the board of directors is 4.1 years and 5.4 years respectively.
Key information
Dan Hicklin
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 42.7% |
| CEO tenure | 7.3yrs |
| CEO ownership | 1.5% |
| Management average tenure | 4.1yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?
Nov 14
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?
Jul 31Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1
Jul 01Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding
Jun 04Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Apr 04Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Feb 07Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise
Dec 09Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates
Sep 30Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 13We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
Jul 08Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Mar 24Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$62m |
| Jun 30 2024 | n/a | n/a | -US$54m |
| Mar 31 2024 | n/a | n/a | -US$42m |
| Dec 31 2023 | US$1m | US$583k | -US$37m |
| Sep 30 2023 | n/a | n/a | -US$37m |
| Jun 30 2023 | n/a | n/a | -US$41m |
| Mar 31 2023 | n/a | n/a | -US$50m |
| Dec 31 2022 | US$2m | US$530k | -US$54m |
| Sep 30 2022 | n/a | n/a | -US$60m |
| Jun 30 2022 | n/a | n/a | -US$62m |
| Mar 31 2022 | n/a | n/a | -US$115m |
| Dec 31 2021 | US$2m | US$498k | -US$202m |
| Sep 30 2021 | n/a | n/a | -US$205m |
| Jun 30 2021 | n/a | n/a | -US$197m |
| Mar 31 2021 | n/a | n/a | -US$127m |
| Dec 31 2020 | US$3m | US$425k | -US$28m |
Compensation vs Market: Dan's total compensation ($USD1.37M) is above average for companies of similar size in the US market ($USD638.68K).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan Hicklin (60 yo)
7.3yrs
Tenure
US$1,366,904
Compensation
Dr. Daniel J. Hicklin, Ph D., also known as Dan, Founded Werewolf Therapeutics, Inc. in October 2017 and has been its President and Chief Executive Officer since August 2019. He serves on its Board of Dire...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 7.3yrs | US$1.37m | 1.45% $ 912.3k | |
| CFO, Treasurer & Assistant Secretary | 4yrs | US$815.59k | 0% $ 0 | |
| Chief Medical Officer | 4.3yrs | US$855.77k | 0% $ 0 | |
| Senior Vice President of Research | less than a year | no data | no data | |
| Chief Technology Officer | 3.7yrs | US$3.86m | no data | |
| Chief Business Officer | 4.5yrs | no data | no data |
4.1yrs
Average Tenure
64yo
Average Age
Experienced Management: HOWL's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 7.3yrs | US$1.37m | 1.45% $ 912.3k | |
| Independent Chairman of the Board | 7.3yrs | US$104.03k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$78.66k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.3yrs | US$62.32k | 0.035% $ 21.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board & Director | 6.5yrs | no data | 0.032% $ 20.3k | |
| Independent Director | 5.5yrs | US$78.53k | 4.59% $ 2.9m | |
| Independent Director | 3.3yrs | US$65.36k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$72.53k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.4yrs
Average Tenure
61yo
Average Age
Experienced Board: HOWL's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 22:55 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Werewolf Therapeutics, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Maneka Mirchandaney | Evercore ISI |
| Andres Maldonado | H.C. Wainwright & Co. |